Avid Bioservices Inc CDMO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDMO is a good fit for your portfolio.
News
-
Avid Bioservices (CDMO) Quantifies Wrongful Accounting Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman
-
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO
-
Investigation into Avid Bioservices, Inc. Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to Know!
-
Avid Bioservices (CDMO) Falls Further After Disclosing Intent to Restate Financial Statements Due to Misclassification of $146 Million of 2026 Notes as Long-Term Liabilities – Hagens Berman
Trading Information
- Previous Close Price
- $7.32
- Day Range
- $7.29–7.68
- 52-Week Range
- $4.07–18.86
- Bid/Ask
- $6.75 / $7.87
- Market Cap
- $466.58 Mil
- Volume/Avg
- 1.3 Mil / 1.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- 67.01
- Price/Sales
- 3.41
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 365
- Website
- https://www.avidbio.com
Comparables
Valuation
|
Metric
|
CDMO
|
ACLX
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 67.01 | — | — |
Price/Book Value | 2.59 | 5.69 | 0.97 |
Price/Sales | 3.41 | 23.01 | — |
Price/Cash Flow | 414.11 | — | — |
Price/Earnings
CDMO
ACLX
EQRX
Financial Strength
|
Metric
|
CDMO
|
ACLX
|
EQRX
|
|---|---|---|---|
Quick Ratio | 0.28 | 5.94 | 18.43 |
Current Ratio | 0.46 | 6.06 | 18.78 |
Interest Coverage | −6.48 | −23.39 | — |
Quick Ratio
CDMO
ACLX
EQRX
Profitability
|
Metric
|
CDMO
|
ACLX
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −1.86% | −6.26% | −15.72% |
Return on Equity (Normalized) | −4.50% | −12.08% | −16.71% |
Return on Invested Capital (Normalized) | −1.60% | −13.11% | −21.31% |
Return on Assets
CDMO
ACLX
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zvslqdvxn | Nlcz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kmmkxxycj | Vbrtkx | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jsvnddm | Rccrmk | $97.8 Bil | |
MRNA
| Moderna Inc | Ngkpygl | Lxwmd | $41.3 Bil | |
ARGX
| argenx SE ADR | Zzmvkqzwl | Pdvl | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ywblywdxn | Kdrw | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ykbqtxssy | Ltdlw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vmxjngrks | Ysbxbb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvqpfqsph | Mgcdgk | $12.5 Bil | |
INCY
| Incyte Corp | Fyvfsrnk | Brlyjzs | $11.6 Bil |